Kanwarpal S. Kahlon, MD
The treatment paradigms of aplastic anemia, immune thrombocytopenic purpura (ITP), and thrombotic thrombocytopenic purpura (TTP) have seen progress within the last year with the approval of eltrombopag (Promacta), avatrombopag (Doptelet), and caplacizumab-yhdp (Cablivi), in these indications, respectively. However, questions still remain and research is needed to develop more effective therapies for patients with these benign hematologic diseases, explained Kanwarpal S. Kahlon, MD.
“Aplastic anemia and transplant [need to be researched more], especially in people who may not have a matched sibling donor or even a matched unrelated donor,” said Kahlon, an assistant clinical professor at the University of California, Los Angeles. “That is an area where there is an unmet need. Transplant can be very effective and seems to be better when given earlier, before donor specific antibodies develop.”
In an interview during the 2019 OncLive® State of the Science SummitTM on Hematologic Malignancies, Kahlon discussed current treatment options for patients with aplastic anemia, ITP, and TTP, as well as future research for the field.
… to read the full story